0001062993-21-007502.txt : 20210813
0001062993-21-007502.hdr.sgml : 20210813
20210813183530
ACCESSION NUMBER: 0001062993-21-007502
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210812
FILED AS OF DATE: 20210813
DATE AS OF CHANGE: 20210813
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CRANDELL KEITH
CENTRAL INDEX KEY: 0001219039
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38720
FILM NUMBER: 211173736
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Twist Bioscience Corp
CENTRAL INDEX KEY: 0001581280
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 462058888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 681 GATEWAY BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 800-719-0671
MAIL ADDRESS:
STREET 1: 681 GATEWAY BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2021-08-12
0001581280
Twist Bioscience Corp
TWST
0001219039
CRANDELL KEITH
C/O ARCH VENTURE PARTNERS IX, LLC
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO
IL
60631
1
0
0
0
Common Stock
2021-08-12
4
S
0
1412
106.93
D
486
D
Common Stock
2021-08-12
4
S
0
41033
106.9765
D
78602
I
By Keith L. Crandell Trust
Common Stock
2021-08-12
4
S
0
2555
107.5638
D
76047
I
By Keith L. Crandell Trust
Common Stock
2021-02-11
4
J
0
286480
0
D
440354
I
By Arch Venture Fund VII, L.P.
Common Stock
2021-02-11
4
J
0
14560
0
A
97252
I
By Keith L. Crandell Trust
Common Stock
2021-02-11
4
J
0
113520
0
D
174584
I
By ARCH Venture Fund VIII Overage, L.P.
Common Stock
2021-02-11
4
J
0
1
0
A
97253
I
By Keith L. Crandell Trust
Common Stock
2021-05-13
4
J
0
214828
0
D
225526
I
By ARCH Venture Fund VII, L.P.
Common Stock
2021-05-13
4
J
0
10918
0
A
108171
I
By Keith L. Crandell Trust
Common Stock
2021-05-13
4
J
0
85172
0
D
89412
I
By ARCH Venture Fund VIII Overage, L.P.
Common Stock
2021-05-13
4
J
0
1
0
A
108172
I
By Keith L. Crandell Trust
Common Stock
2021-05-19
4
J
0
225526
0
D
0
I
By ARCH Venture Fund VII, L.P.
Common Stock
2021-05-19
4
J
0
11462
0
A
119634
I
By Keith L. Crandell Trust
Common Stock
2021-05-19
4
J
0
89412
0
D
0
I
By ARCH Venture Fund VIII Overage, L.P.
Common Stock
2021-05-19
4
J
0
1
0
A
119635
I
By Keith L. Crandell Trust
Pro-rata distribution of Common Stock held by a limited partnership to its partners for no consideration.
The shares were directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
The shares were directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Keith Crandell is a managing director of ARCH VII LLC and ARCH VIII LLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Change in form of ownership of shares previously reported as beneficially owned by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.39 to $107.37. The reporting person undertakes to provide to TWST, any security holder of TWST, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (6) and (7) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.405 to $107.70.
/s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell
2021-08-13